WallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BMY

Based on 11 analysts offering 12 month price targets for Bristol Myers Squibb Co.
Min Forecast
$65.00+1.28%
Avg Forecast
$72.82+13.46%
Max Forecast
$80.00+24.65%

Should I buy or sell BMY stock?

Buy
Strong Buy
8 analysts 53.33%
Buy
1 analysts 6.67%
Hold
6 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is BMY forecast to generate an efficient return?
Company
37.39%
Industry
75.15%
Market
62.3%
BMY's Return on Equity is forecast to be high in 4 years (37.39%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is BMY forecast to generate an efficient return on assets?
Company
14.94%
Industry
16.93%
Market
19.84%
BMY is forecast to generate lower Return on Assets (14.94%) than the US Drug Manufacturers - General industry average (16.93%)
Forecast

BMY earnings per share forecast

What is BMY's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$7.32-2,714.29%
Avg 2 year Forecast
$7.80-2,886.32%
Avg 3 year Forecast
$8.13-3,003.57%

BMY revenue forecast

What is BMY's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$45.4B+15.25%
Avg 2 year Forecast
$47.1B+19.44%
Avg 3 year Forecast
$49.0B+24.4%
BMY's revenue is forecast to grow at a rate of 7.49% per year, which is not exceptional
Forecast

BMY revenue growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
7.49%
Industry
6.43%
Market
14.47%
BMY's revenues are forecast to grow faster (7.49% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
BMY's revenues are forecast to grow slower (7.49% per year) than the US market average (14.47%)
Forecast

Bristol Myers Squibb Stock Forecast FAQ

Is Bristol Myers Squibb Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NYSE: BMY) stock is to Buy BMY stock.

Out of 15 analysts, 8 (53.33%) are recommending BMY as a Strong Buy, 1 (6.67%) are recommending BMY as a Buy, 6 (40%) are recommending BMY as a Hold, 0 (0%) are recommending BMY as a Sell, and 0 (0%) are recommending BMY as a Strong Sell.

What is BMY's Price Target?

According to 11 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $72.82, with the highest BMY stock price forecast at $80.00 and the lowest BMY stock price forecast at $65.00.

On average, Wall Street analysts predict that Bristol Myers Squibb's share price could reach $72.82 by Jan 14, 2022. The average Bristol Myers Squibb stock price prediction forecasts a potential upside of 13.46% from the current BMY share price of $64.18.

What is BMY's earnings growth forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Bristol Myers Squibb's earnings in 2020 is -$44,000,000.On average, 8 Wall Street analysts forecast BMY's earnings for 2021 to be $16,498,801,528, with the lowest BMY earnings forecast at $15,642,306,367, and the highest BMY earnings forecast at $16,814,352,377. On average, 6 Wall Street analysts forecast BMY's earnings for 2022 to be $17,584,521,842, with the lowest BMY earnings forecast at $16,881,970,416, and the highest BMY earnings forecast at $18,031,477,080.

In 2023, BMY is forecast to generate $18,324,488,583 in earnings, with the lowest earnings forecast at $17,580,690,153 and the highest earnings forecast at $19,361,298,515.

What is BMY's revenue growth forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's forecast annual revenue growth rate of 7.49% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.

Bristol Myers Squibb's revenue in 2020 is $39,395,000,000.On average, 5 Wall Street analysts forecast BMY's revenue for 2021 to be $102,330,620,399,348, with the lowest BMY revenue forecast at $101,352,002,551,655, and the highest BMY revenue forecast at $102,931,334,550,399. On average, 5 Wall Street analysts forecast BMY's revenue for 2022 to be $106,055,008,466,614, with the lowest BMY revenue forecast at $104,118,188,911,151, and the highest BMY revenue forecast at $109,041,075,165,494.

In 2023, BMY is forecast to generate $110,455,944,315,726 in revenue, with the lowest revenue forecast at $108,919,137,301,740 and the highest revenue forecast at $113,507,021,251,283.

What is BMY's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: BMY) Bristol Myers Squibb's current Earnings Per Share (EPS) is -$0.28. On average, analysts forecast that BMY's EPS will be $7.32 for 2021, with the lowest EPS forecast at $6.94, and the highest EPS forecast at $7.46. On average, analysts forecast that BMY's EPS will be $7.80 for 2022, with the lowest EPS forecast at $7.49, and the highest EPS forecast at $8.00. In 2023, BMY's EPS is forecast to hit $8.13 (min: $7.80, max: $8.59).

What is BMY's forecast return on equity (ROE) for 2021-2024?

(NYSE: BMY) forecast ROE is 37.39%, which is considered strong.

What is BMY's forecast return on assets (ROA) for 2021-2024?

(NYSE: BMY) forecast ROA is 14.94%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.93%.
WallStreetZen
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatistics
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics